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Introduction
Staphylococcus pseudintermedius is a normal inhabitant of
the skin and mucosa and can be isolated from the nares,
mouth, pharynx, forehead, groin and anus of healthy dogs and
cats  (Rubin and Chirino-Trejo, 2011). Though it is an oppor-
tunistic pathogen,  S. pseudintermedius is a leading cause of
skin and ear infections and post-operative wound infections
in dogs and cats (Weese and Duijkeren 2010; Mohammad et
al., 2015). This bacterial pathogen has also been linked to se-
vere infections in companion animals including urinary tract
infections, complicated skin infections, surgical site infections,
and otitis (Weese et al., 2012).
The challenge of treating infections caused by S. pseudin-
termedius has become more troublesome with the isolation
of strains displaying resistance to numerous antibacterial
classes including β-lactams, fluoroquinolones, lincosamides,
macrolides, aminoglycosides, tetracyclines, sulfonamides, and
chloramphenicol  (Perreten et al. 2010; Weese and Duijkeren
2010; Eckholm et al., 2013). Of these strains, methicillin-resis-
tant S. pseudintermedius (MRSP) isolates are particularly trou-
bling. Resistance to methicillin and other β-lactam antibiotics
is mediated by the mecA gene that encodes a modified peni-
cillin binding protein (PBP), similar to methicillin-resistant S.
aureus (MRSA) (van Duijkeren et al., 2011). Usually, β-lactam
antibiotics attach to the PBP of S. pseudintermedius and inter-
fere with proper formation of the bacterial cell wall. MRSP iso-
lates are frequently not only resistant to β-lactam antibiotics,
but also to several other classes of antimicrobial drugs. Thus
treatment of MRSP infections is an emerging challenge in vet-
erinary medicine because of limited therapeutic options
(Wettstein et al., 2008). Hence, there is a need for antibacterial
agents capable of inhibiting previously unexploited drug tar-
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Staphylococcus pseudintermedius is a component of the normal flora of companion animals that
contributes to opportunistic infections in dogs. Clinical isolates of S. pseudintermedius (chiefly
methicillin-resistant S. pseudintermedius (MRSP)) have been identified that exhibit resistance to
nearly all antibiotic classes. There is a need for new antibiotics that target novel pathways within
resistant pathogens such as MRSP. A possible novel antibacterial target in Gram-positive cocci is
class II HMG-CoA reductase (HMGR), a key enzyme present in the mevalonate pathway that is
essential for bacterial survival. In this study, we examined novel synthetic compounds that are
potent inhibitors of bacterial HMGRs. The compounds inhibited growth, in low micromolar con-
centration, of clinical isolates of methicillin-sensitive S. pseudintermedius (MSSP) and MRSP via
the broth microdilution assay. The MTS assay confirmed the most potent compound (6) was not
toxic to different mammalian cell lines (up to 128 µM). A time-kill assay revealed this compound
rapidly eradicates a high inoculum of MRSP within two hours. This study provides evidence that
compound 6 is a promising agent that warrants further investigation as a novel treatment option
for MRSP infections. 
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gets to treat infections caused by methicillin-sensitive and me-
thicillin-resistant S. pseudintermedius. One such target is the
3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR) enzyme.
There are two distinct classes of HMGR. Class I HMGR is
present in all eukaryotes and some archaea while Class II
HMGR is present only in prokaryotes (Bochar et al., 1999).
HMGR catalyzes the first committed reaction of the meval-
onate pathway for biosynthesis of isoprenoids (Edwards and
Ericsson, 1998). While most bacteria synthesize isopentenyl
diphosphate by the alternative non-mevalonate 2-C-methyl-
D-erythritol 4-phosphate/1-deoxy-D-xylulose 5-phosphate
pathway (MEP/DOXP) pathway, isoprenoids in S. aureus are
synthesized through a mevalonate pathway with a Class II
HMGR (Wilding et al., 2000). Clearly HMGR represents a po-
tential target for antibacterial agents directed against mul-
tidrug-resistant strains including MRSP. In spite of the
attractive features offered by HMGR as a potential therapeutic
target for antibiotic drug development, a very limited number
of inhibitors have been reported (Hedl and Rodwell, 2004).
With this point in mind, the present study aimed to identify
small molecule inhibitors (designed to target bacterial HMGR)
that possess potent antibacterial activity against S. pseudin-
termedius and exhibit limited toxicity to mammalian cells. 
Materials and methods
Methicillin-resistant Staphylococcus aureus USA300
(MRSA) and Pseudomonas aeruginosa ATCC 15442 were ob-
tained from BEI Resources and the American Tissue Culture
Collection, respectively. Fifteen isolates of Staphylococcus
pseudintermedius (6 methicillin-sensitive S. pseudintermedius
(MSSP) and 9 methicillin-resistant S. pseudintermedius (MRSP))
were included in the study (Table 1). The specimens were ob-
tained from patients admitted to the Purdue University small
animal hospital for treatment and confirmed by the Indiana
Animal Disease Diagnostic Laboratory. Clinical specimens were
inoculated onto 5% sheep blood agar and incubated at 35 ˚C
for 18–24 hours. Standard methods including examination of
colony morphology and hemolysis and biochemical tests such
as tube coagulase, Voges-Proskauer (VP) and fermentation
tests for maltose, trehalose and lactose, were used to identify
isolates (Murugaiyan et al., 2014) and (Versalovic, 2011). An-
timicrobial susceptibility was determined via the broth mi-
crodilution assay using the SensiTitre (Trek). Isolates
demonstrating resistance to oxacillin (minimum inhibitory
concentration (MIC) greater than or equal to 0.5 mg/ mL), a
surrogate for methicillin, were screened for mecA by PCR, as
previously described (Vannuffel et al., 1995). A mecA positive
result was assigned to samples with a visible 310 bp band on
a 1.5% agarose gel.
Clindamycin hydrochloride monohydrate was purchased
from Tokyo Chemical Industry (Portland, OR, USA) and ri-
fampicin was purchased from Sigma-Aldrich (St. Louis, MO,
USA). The compounds presented in this study are derivatives
of 5-(N-(4-butylphenyl) sulfa moyl)-2-hydroxybenZoic acid 1
(N-bsha) and were synthesized by Dr. Mark Lipton’s research
group at Purdue University. The compounds were confirmed
to inhibit the bacterial HMGR enzyme by Dr. Cynthia Stauf-
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Table 1. Clinical isolates of Staphylococcus pseudintermedius (SP) used in this study
Abbreviations: PEN: penicillin, AMP, ampicillin, AMK: amikacin, CEF: cefpodxime, CLIN: clindamycin, GEN: gentamicin, CHL: chloramphenicol,
ENR: enrofloxacin, MARB: marbofloxacin, ERM: erythromycin, BAC: bacitracin, NEO: neomycin, TOB: tobramycin, CIP: ciprofloxacin, OXY: Ox-
ytetracycline, TEM-SMX: trimethoprim-sulfamethoxazole
facher’s research group at Purdue University (data not pub-
lished). All antibiotics and compounds were dissolved in di-
methyl sulfoxide (DMSO) to obtain a stock 10 mM solution.
Murine macrophages (J774A.1), human keratinocytes
(HaCat), and human ileocecal colorectal (HRT-18) cell lines and
fetal horse serum were purchased from the American Tissue
Culture Collection (Manassas, VA, USA). Trypticase soy agar
(TSA), Trypticase soy broth (TSB) were purchased from Becton,
Dickinson and Company (Cockeysville, MD, USA). Phosphate
buffered saline (PBS), Mueller-Hinton broth (MHB) and Dul-
becco’s Modified Eagle Medium (DMEM) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). The MTS reagent for tox-
icity assessment was purchased commercially (Promega,
Madison, WI, USA).
Primary screening of class II HMGR inhibitors against clinical
isolates of MRSA and Pseudomonas aeruginosa
The MIC and minimum bactericidal concentration (MBC)
of the 15 compounds was initially determined against methi-
cillin-resistant Staphylococcus aureus (MRSA) and
Pseudomonas aeruginosa using the broth microdilution
method according to the Clinical and Laboratory Standards
Institute (CLSI) guidelines (CLSI, 2007). The most potent com-
pound (6) was subsequently tested against clinical isolates of
S. pseudintermedius, as described below.
The MIC and MBC of compound 6 against clinical isolates of
MSSP and MRSP.
The MIC of compound 6, rifampicin, and clindamycin
against nine isolates of MRSP and six isolates MSSP was de-
termined using the broth microdilution method in accordance
with the recommendations contained in the CLSI guidelines
(Mohammad et al., 2015). Bacteria were prepared in phos-
phate-buffered saline (PBS) to achieve a McFarland standard
of 0.5. The solution was subsequently diluted 1:300 in Mueller-
Hinton broth (MHB) for MRSP and MSSP to reach a starting
inoculum of 1×105 colony-forming units (CFU/mL). Bacteria
were then transferred to a 96-well microtiter plate. Compound
6, rifampicin, and clindamycin were added (in triplicate) to
wells in the first row of the microtiter plate and serially diluted
two-fold. The plate was incubated at 37ºC for 18-20 hours be-
fore the MIC was recorded as the lowest concentration where
no bacterial growth was observed. The MBC was determined
by plating 5 µL from wells on the 96-well microtiter plate
where no growth was observed, onto TSA plates. The plates
were incubated at 37 ºC for 18-20 hours before the MBC was
determined. The MBC was classified as the concentration
where ≥ 99% reduction in bacterial cell count was observed.
Time-kill kinetic analysis
MRSP SP3 cells in late logarithmic growth phase were di-
luted to ~1×106 colony-forming units (CFU/mL) and exposed
to concentrations equal to 3×MIC or 5×MIC  (in triplicate) of
compound 6, clindamycin, or rifampicin in TSB. Samples (20
µL) were collected after 0, 2, 4, 6, 8, 10, and 12 hours of incu-
bation at 37ºC and then serially diluted in PBS. Bacteria were
transferred to TSA plates and incubated at 37ºC for 18-20
hours before viable CFU/mL was determined as previously de-
scribed (Mohammad et al., 2015).
In vitro cytotoxicity analysis
HMGR inhibitor compound 6 assayed against murine
macrophage cells (J774A.1)
Compound 6 was assayed at concentrations of 16, 32, 64,
and 128 µM against a murine macrophage-like cell line
(J774A.1) to determine the potential toxic effect in vitro. Briefly,
J774A.1 cells were seeded at a density of 1.56×104 per well in
a tissue culture 96-well plate (CytoOne, CC7682-7596) in
DMEM media supplemented with 10% fetal bovine serum
(FBS), and incubated at 37˚C in a 5% CO2 atmosphere for 24
hours. The cells were treated with HMGR inhibitor at for 24
hours. Untreated cells were used as a negative control. After
incubation, the cells were washed three times with PBS and
before addition of the reagent, MTS 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetra-
zolium). Cells were incubated further for four hours at 37 ˚C
with 5% CO2. Corrected absorbance readings (actual ab-
sorbance readings for each treatment subtracted from back-
ground absorbance) were taken using a kinetic ELISA
microplate reader (Molecular Devices, Sunnyvale, CA, USA).
Cell viability was expressed as percent absorbance in compar-
ison to the negative control (untreated cells) as reported else-
where  (Bahnsen et al., 2013; Mohamed et al., 2014).
Compound 6 assayed against a human keratinocyte cell line
(HaCat)
Human keratinocyte (HaCat) cells were seeded at a density
of 10,000 cells per well in a 96-well tissue culture plate (Cy-
toOne, CC7682-7596) in DMEM media containing 10% fetal
bovine serum (FBS) and incubated overnight at 37°C. Then
cells were treated with compound 6 at concentrations of 16,
32, 64, and 128 µM for 24 hours. Treated cells were washed
three times with PBS and DMEM media containing MTS assay
reagent was added to each well. After four hours of incubation
at 37 °C, absorbance was measured using ELISA microplate
reader. Percent cell viability of cells treated with compound 6
were calculated relative to the untreated cells according to
(Thangamani et al., 2015).
Compound 6 assayed against a human ileocecal colorectal cell
line (HRT-18)
Human  ileocecal colorectal cell line (HRT-18)  cells were
seeded at a density of 10,000 cells per well in a 96-well tissue
culture plate (CytoOne, CC7682-7596) in RPMI-1640 supple-
mented with 10% fetal horse serum and incubated overnight
at 37°C. Cells were treated with compound 6 at concentrations
of 16, 32, 64, and 128 µM for 24 hours. Treated cells were
washed three times with PBS before addition of DMEM media
containing MTS assay reagent. After four hours of incubation
at 37°C, absorbance was measured using an ELISA microplate
reader. The percent cell viability of cells treated with com-
pound 6 was calculated relative to the untreated cells. 
Statistical analysis
Statistical analysis was completed using GraphPad Prism
6.0 (GraphPad Software, La Jolla, CA). Statistical significance
was determined using the two-tailed Student's t-test. P values
of < 0.05 were considered significant. Data are presented as
mean ± SD.
Results
Antibacterial activity of 15 class II HMGR inhibitors tested
against S. aureus and P. aeruginosa
The antibacterial activity of 15 synthesized  class II HMGR
inhibitors were initially evaluated against one Gram-positive
(MRSA USA300) and one Gram-negative  bacterial pathogen,
Pseudomonas aeruginosa ATCC 15442. As presented in Table
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2, five  compounds 5, 6, 9, 10, and 12 were  capable of inhibit-
ing MRSA USA300 growth at concentrations ranging from16
μM to 64 μM. Interestingly, none of the compounds examined
possessed antibacterial activity against P. aeruginosa ATCC
15442 which has the alternative MEP/DOXP isoprenoid
biosynthesis pathway (MIC>128 μM). This indicates the anti-
bacterial activity of the designed inhibitors may be restricted
to Gram-positive pathogens. 
From the initial screening results, compound 6 emerged
as the most potent inhibitor of S. aureus growth. Thus we
moved next to examine compound 6 for its ability to inhibit
growth of important multidrug-resistant strains of MRSP and
MSSP
Antibacterial activity of compound 6 against Staphylococcus
pseudintermedius
The antibacterial activity of compound 6 was tested
against a panel of clinical isolates of methicillin-sensitive and
methicillin-resistant S. pseudintermedius (Table 3). Against iso-
lates of MSSP, compound 6 inhibited growth consistently at a
concentration of 8 µM. When 6 was evaluated against MRSP,
there was a one-fold increase in the MIC observed (MIC was
16 µM against most isolates). This MIC value correlates well 
with the MIC noted for compound 6 against MRSA. Control
antibiotics rifampicin and clindamycin inhibited growth of
most S. pseudintermedius isolates at a concentration of ≤ 0.5
µM and 1 µM, respectively. Interestingly, compound 6 retained
its potent antibacterial activity against four isolates of S. pseud-
intermedius exhibiting resistance to clindamycin (SP2, SP28,
SP40, and SP41) indicating cross-resistance between 6 and
clindamycin is unlikely to occur. Compound 6 showed bacte-
ricidal activity against both MRSP and MSSP strains with a
minimum bactericidal concentration (MBC) ranging from 16
to 32 µM. This behavior is similar to the antibiotics rifampicin
and clindamycin.
Time-kill assay of compound 6 versus MRSP
Preliminary data from the MBC study indicated compound
6 is bactericidal against S. pseudintermedius. In order to con-
firm this result, a time-kill assay was conducted with com-
pound 6, rifampicin, and clindamycin against MRSP SP3. As
depicted in Fig. 1, compound 6 mimics the behavior of ri-
fampicin as both agents completely eradicate a high inoculum
of MRSP within two hours. No re-growth of bacteria is ob-
served over the remaining ten hour sampling period. In con-
trast, clindamycin requires eight hours to achieve the same
result. 
Fig. 1. Time-kill assay of compound 6, rifampicin, and clindamycin
against MRSP. Compound 6, rifampicin and clindamycin were incu-
bated with MRSP SP3 (~9.6 × 105 CFU/ml) and samples were collected
every two hours to enumerate viable CFU/mL. Panel A) 3 × MIC of test
agent and Panel B) 5 × MIC of test agent The error bars represent
standard deviation values obtained from triplicate samples used for
compound/antibiotic studied.
Fig. 2. Toxicity examination of compound 6 against multiple mam-
malian cell lines. Compound 6 was examined at 16, 32, 64, and 128
µM against three different cell lines A) Murine macrophage cell line
(J774.1), B) human keratinocyte cells (HaCaT), and C) human colorectal
cells (HRT-18) using the MTS assay. An unpaired t–test (P < 0.05) was
used to evaluate toxicity of cells exposed to compound 6 compared
to cells treated with DMSO.
Table 2. The MIC and MBC of HMG-CoA reductase inhibitors tested
against methicillin-resistant Staphylococcus aureus (MRSA) and
Pseudomonas aeruginosa.
Table 3. MIC and MBC of compound 6, rifampicin, and clindamycin
against MSSP and MRSP clinical isolates.
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Irrespective of the concentration tested (3× or 5× MIC), the
same result is observed indicating the compound and drugs
do not exhibit a concentration-dependent effect. The time-kill
assay confirms the result obtained with the MBC study, prov-
ing that compound 6 is in fact a bactericidal agent.
Toxicity analysis of compound 6 against mammalian cells
Confirmation of compound 6’s potent antibacterial activity
led us to next investigate whether this compound is toxic to
mammalian tissues. Compounds that exhibit toxicity to host
(mammalian) tissues possess limited therapeutic utility as an-
tibacterial agents.  Thus we evaluated compound 6 for poten-
tial toxicity to three different cell lines (Fig. 2). Against murine
macrophage cells (J774), compound 6 was found to be non-
toxic at the highest concentration tested (128 µM). The same
result was obtained for compound 6 examined against human
keratinocytes (Fig. 5B) and human colorectal cells (Fig. 5C).
This represents a greater than 16-fold difference between the
MIC of compound 6 against S. pseudintermedius and the high-
est concentration tested for toxicity against all three mam-
malian cell lines. Collectively, this demonstrates compound 6
exhibits limited toxicity to mammalian cells.
Discussion
Staphylococcus pseudintermedius infections are an emerg-
ing issue in veterinary medicine; until recently, most diseases
observed in small animal veterinary services were amenable
to treatment with a variety of antimicrobials (Beco et al., 2013).
Be that as it may, the quick development and worldwide
spread of multidrug-resistant S. pseudintermedius (to be spe-
cific MRSP) in the previous ten years has exhibited a notewor-
thy challenge to veterinary specialists (Jones et al., 2007;
Ruscher et al., 2009). Clinical isolates have been recognized
that display resistance to various antibiotic classes, reducing
the treatment alternatives available to veterinarians. This un-
derscores the need to develop new antimicrobials to battle
this significant medicinal challenge. 
Most antibiotics target the same essential processes in
bacteria such as cell wall synthesis (β-lactams and glycopep-
tides), protein synthesis (oxazolidinones, tetracyclines, and
aminoglycosides), and DNA (quinolones) or RNA synthesis (ri-
fampicin) (Payne et al., 2007). Astoundingly, more than 40%
of antibiotics target cell wall synthesis. However, studies have
identified bacteria, such as S. aureus, encode for multiple es-
sential genes that represent a potential reservoir of novel an-
tibacterial targets (Silver, 2007; Zoraghi et al., 2011; Haag et
al., 2012) . One of these targets is the mevalonate pathway
which is essential for the survival of Gram-positive cocci. One
gene of interest in this pathway is the HMG-CoA reductase
gene. This target differs from human and animal HMG-CoA
reductase in catalytically important residues and in regions of
the proteins that participate in oligomerization (Istvan,  2001). 
To date, no chemical compounds have been designed thus
far that specifically target bacterial HMG-CoA reductase. Thus
the present study aimed to examine 15 derivatives of 5-(N-(4-
butylphenyl) sulfamoyl)-2-hydroxybenZoic acid 1 (N-bsha)
which inhibit the HMGR coenzyme of S.aureus at low concen-
tration (5 µM). We initially screened the antibacterial activity
of the 15 compounds against one Gram-positive (MRSA
USA300) and one Gram-negative (Pseudomonas aeruginosa
ATCC 15442). We found five class II HMGR inhibitors were ca-
pable of inhibiting MRSA USA300 growth with a minimum in-
hibitory concentration (MIC) value ranging from 16 μM to 64
μM. None of the compounds were active against P. aeruginosa
ATCC 15442. Of the compounds screened, compound 6 was
the most potent inhibitor of MRSA USA300 grwoth (MIC = 16
μM ). As S. pseudintermedius and S. aureus have comparable
hereditary and phenotypic traits, we hypothesized that com-
pound 6 would exhibit potent antibacterial activity against
both MSSP and MRSP. Therefore, the MIC and MBC of com-
pound 6 was tested against nine clinical isolates of MRSP and
six clinical isolates of MSSP. As predicted, compound 6 exhib-
ited potent antibacterial activity against clinical isolates of
MSSP and MRSP (MIC ranged from 8-16 µM). Though the
compound was not as potent as clindamycin (MIC ranged
from 0.5 to >128 against both MSSP and MRSP), which is a
first-line treatment option for treatment of S. pseudintermedius
pyoderma infections (Beco et al., 2013), compound 6 was
more effective that this drug against four strains of S. pseud-
intermedius exhibiting resistance to clindamycin. 
Interestingly, compound 6 maintained its antibacterial ac-
tivity against six MSSP and nine MRSP isolates which were
found to be resistant to clindamycin and other antibiotics; this
indicates there is no cross-resistance present between these
antibiotics and the compound 6. This promote the concept
that this compound 6 have possible to be used as new anti-
bacterial agents, especially against S. pseudintermedius infec-
tions resistant to treatment with other antibiotics. 
We were interested to examine if compound 6 is a bacte-
riostatic or bactericidal agent. It has been suggested that bac-
tericidal antimicrobials have several advantages over their
bacteriostatic counterparts, including helping patients recoup
more quickly from infection, decreasing the potential devel-
opment of bacterial resistance  to these antibiotics, and re-
stricting the spread of infection (French, 2006). Initial analysis
revealed compound 6 was bactericidal as its MBC was identical
to or two-fold higher than its MIC values against both MSSP
and MRSP isolates. To confirm this result, a time-kill assay was
conducted. This assay revealed that compound 6 is a rapid
bactericidal agent as it eliminated MRSP within two hours. This
result was similar to the result obtained with rifampicin, an an-
tibiotic frequently used in combination with other antibiotics
to treat pyoderma infections (Beco et al., 2013).. Thus one po-
tential advantage of compound 6’s rapid bactericidal activity
is it may help to resolve an infection more quickly.
To confirm the compound 6 selectively targets bacterial
HMG-CoA reductase and not the mammalian homolog, the
toxicity of compound 6  was tested against different cell lines.
Against three different cell lines (J774, HaCaT and  HRT-18)
compound 6 was not toxic at concentrations up to 128 µM
(an 8 to 16-fold difference from the compound’s MIC values
against S. pseudintermedius). This indicates compound 6 ex-
hibits limited toxicity to mammalian tissues and warrants fur-
ther investigation as a novel antibacterial agent for treatment
of infections caused by S. pseudintermedius. 
Conclusion
In this study we have demonstrated novel HMGR coen-
zyme inhibitors, synthesized by our research group, are potent
inhibitors of staphylococcal growth. One of these inhibitors
(compound 6) exhibits potent antibacterial activity against
clinical isolates of methicillin-sensitive and methicillin-resistant
S. pseudintermedius. This compound is capable of inhibiting
bacterial growth at low micromolar concentrations even
against isolates exhibiting resistance to the drug of choice
(clindamycin) for treatment of canine pyoderma infections.
This compound is bactericidal and exhibit superior killing ki-
netics to clindamycin as it completely eliminates a high inocu-
lum of MRSP within two hours.  Compound 6 appears to be
the most suitable HMGR coenzyme inhibitor to examine in
further studies involving S. pseudintermedius as it is not toxic
to mammalian cells at a concentration that is 8 or16-fold
higher than its MIC. Finally, this study provides a basis for ad-
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ditional analysis and expansion of HMGR inhibitors novel
treatment options for infections caused by multidrug-resistant
pathogens that possess the mevalonate pathway
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